A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

CONCLUSION: Sequential administration of eribulin after the A/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.PMID:34554370 | DOI:10.1007/s10549-021-06396-0

Source: Cell Research - September 23, 2021 Category: Cytology Authors: Ippei Fukada Yoshinori Ito Naoto Kondo Shoichiro Ohtani Masaya Hattori Eriko Tokunaga Nobuki Matsunami Kohjiro Mashino Taijiro Kosaka Masahiko Tanabe Daisuke Yotsumoto Kosho Yamanouchi Masataka Sawaki Masahiro Kashiwaba Hidetaka Kawabata Katsumasa Kuroi S Source Type: research